Platform Purification of Six Biosimilar Molecules Using Amsphere A3 – Protein A Resin

View PDF

Currently more than 70 biosimilar mAbs (monoclonal antibodies) are under development and multiple originator mAbs are going off-patent in the next 3-4 years. Protein A resin remains the most important workhorse for the purification of monoclonal antibodies.
Protein A resin has a high impact on both development and manufacturing cost,
in particular during early stage clinical phases. This application note summarizes the key performance parameters for our high capacity protein A resin, Amsphere A3, for 6 biosimilar molecules of which five are mAbs and one is a Fc-fusion protein.